Patents by Inventor Harald Juppner
Harald Juppner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9057727Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: GrantFiled: September 25, 2013Date of Patent: June 16, 2015Assignees: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, Jr., Masaru Shimizu, Fumihiko Ichikawa, Harald Jüppner, Makoto Okazaki
-
Publication number: 20140086842Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: ApplicationFiled: September 25, 2013Publication date: March 27, 2014Applicants: Chugai Pharmaceutical Co., Ltd., The General Hospital CorporationInventors: Thomas J. GARDELLA, John T. Potts, JR., Masaru Shimizu, Fumihiko Ichikawa, Harald Jüppner, Makoto Okazaki
-
Patent number: 8568737Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: GrantFiled: August 1, 2008Date of Patent: October 29, 2013Assignees: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, Jr., Masaru Shimizu, Fumihiko Ichikawa, Harald Juppner, Makoto Okazaki
-
Publication number: 20130116180Abstract: Disclosed are two PTH analog ligands, SP-PTH-AAK and Aib-SP-PTH-AAK, that have long-acting activity at the PTH receptor, as demonstrated both in vitro and in vivo. These polypeptides are thus particularly useful in the treatment of diseases, such as hypoparathyroidism, in which long-acting activity is desired. The method of making the analog polypeptides is also disclosed.Type: ApplicationFiled: May 12, 2011Publication date: May 9, 2013Applicants: Chugai Seiyaku Kabushiki Kaisha, The General Hospital CorporationInventors: Thomas J. Gardella, John T. Potts, JR., Harald Juppner, Makoto Okazaki
-
Patent number: 7985835Abstract: Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing such peptides, and synthetic and recombinant methods for producing such peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing such peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of such compounds.Type: GrantFiled: November 13, 2006Date of Patent: July 26, 2011Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Harald Jüppner
-
Publication number: 20110172153Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: ApplicationFiled: August 1, 2008Publication date: July 14, 2011Applicants: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, JR., Masaru Shimizu, Fumihiko Ichikawa, Harald Juppner, Makoto Okazaki
-
Patent number: 7371844Abstract: Parathyroid hormone(PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.Type: GrantFiled: July 8, 2005Date of Patent: May 13, 2008Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Juppner
-
Publication number: 20080058505Abstract: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1-34) fragment are disclosed that combine the N-terminal signaling domain (residues 1-9) and the C-terminal binding domain (residues 15-31) via a linker. Nucleic acid molecules and peptides for PTH(1-9)-(Gly)5-PTH(15-31) (PG5) and PTH(1-9)-(Gly)7-PTH(15-31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.Type: ApplicationFiled: June 18, 2007Publication date: March 6, 2008Inventors: Thomas Gardella, Henry Kronenberg, John Potts, Harald Juppner
-
Patent number: 7270968Abstract: The invention relates to a mammalian cell lacking type-1 parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) receptor (PTH1R) activity and containing carboxyl-terminal parathyroid hormone receptor (CPTHR) activity. The invention also relates to a method of screening for agonists or antagonists for CPTHR.Type: GrantFiled: August 14, 2001Date of Patent: September 18, 2007Assignee: The General Hospital CorporationInventors: F. Richard Bringhurst, Paola Divieti, Harald Jüppner
-
Patent number: 7244834Abstract: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1–34) fragment are disclosed that combine the N-terminal signaling domain (residues 1–9) and the C-terminal binding domain (residues 15–31) via a linker. Nucleic acid molecules and peptides for PTH(1–9)-(Gly)5-PTH(15–31) (PG5) and PTH(1–9)-(Gly)7-PTH(15–31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.Type: GrantFiled: March 3, 2006Date of Patent: July 17, 2007Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Jüppner
-
Publication number: 20070111946Abstract: Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing such peptides, and synthetic and recombinant methods for producing such peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing such peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of such compounds.Type: ApplicationFiled: November 13, 2006Publication date: May 17, 2007Inventors: Thomas Gardella, Henry Kronenberg, John Potts, Harald Juppner
-
Patent number: 7153951Abstract: Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing such peptides, and synthetic and recombinant methods for producing such peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing such peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of such compounds.Type: GrantFiled: July 11, 2002Date of Patent: December 26, 2006Assignee: The General Hospital CorporationInventors: Thomas J Gardella, Henry M Kronenberg, John T Potts, Jr., Harald Jüppner
-
Patent number: 7150974Abstract: DNA encoding a parathyroid hormone receptor; production and isolation of recombinant and synthetic parathyroid hormone receptor polypeptides and fragments; antibodies to parathyroid hormone receptors and receptor fragments; methods for screening candidate compounds for antagonistic or agonistic effects on parathyroid hormone receptor action; and diagnostic and therapeutic methods of these compounds are disclosed.Type: GrantFiled: November 24, 1998Date of Patent: December 19, 2006Assignee: The General Hospital CorporationInventors: Gino V. Segre, Henry M. Kronenberg, Abdul-Badi Abou-Samra, Harald Juppner, John T. Potts, Jr., Ernestina Schipani
-
Patent number: 7132260Abstract: DNA encoding a parathyroid hormone receptor; production and isolation of recombinant and synthetic parathyroid hormone receptor polypeptides and fragments; antibodies to parathyroid hormone receptors and receptor fragments; methods for screening candidate compounds for antagonistic or agonistic effects on parathyroid hormone receptor action; and diagnostic and therapeutic methods of these compounds are disclosed.Type: GrantFiled: October 9, 2002Date of Patent: November 7, 2006Assignee: The General Hospital CorporationInventors: Gino V. Segre, Henry M. Kronenberg, Abdul-Badi Abou-Samra, Harald Juppner, John T. Potts, Jr., Ernestina Schipani
-
Publication number: 20060228353Abstract: The present invention relates to novel parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrP) receptors (PTH1R and PTH3R) isolated from zebrafish. The receptors of the present invention share homology with previously identified parathyroid hormone (PTH)/parathyroid related protein (PTHrP) receptors. Isolated nucleic acid molecules are provided encoding the zebrafish PTH1R and PTH3R receptors. PTH1R and PTH3R receptor polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of PTH1R and PTH3R receptor activity and to diagnostic and therapeutic methods.Type: ApplicationFiled: May 25, 2006Publication date: October 12, 2006Applicant: The General Hospital CorporationInventors: Harald Juppner, David Rubin
-
Publication number: 20060199765Abstract: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1-34) fragment are disclosed that combine the N-terminal signaling domain (residues 1-9) and the C-terminal binding domain (residues 15-31) via a linker. Nucleic acid molecules and peptides for PTH(1-9)-(Gly)5-PTH(15-31) (PG5) and PTH(1-9)-(Gly)7-PTH(15-31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.Type: ApplicationFiled: March 3, 2006Publication date: September 7, 2006Inventors: Thomas Gardella, Henry Kronenberg, John Potts, Harald Juppner
-
Patent number: 7078487Abstract: The present invention relates to novel parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrP) receptors (PTH1R and PTH3R) isolated from zebrafish. The receptors of the present invention share homology with previously identified parathyroid hormone (PTH)/parathyroid related protein (PTHrP) receptors. Isolated nucleic acid molecules are provided encoding the zebrafish PTH1R and PTH3R receptors. PTH1R and PTH3R receptor polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of PTH1R and PTH3R receptor activity and to diagnostic and therapeutic methods.Type: GrantFiled: February 25, 2003Date of Patent: July 18, 2006Assignee: The General Hospital CorporationInventors: Harald Jüppner, David A Rubin
-
Patent number: 7057012Abstract: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1–34) fragment are disclosed that combine the N-terminal signaling domain (residues 1–9) and the C-terminal binding domain (residues 15–31) via a linker. Nucleic acid molecules and peptides for PTH(1–9)-(Gly)5-PTH(15–31) (PG5) and (1–9)-(Gly)7-PTH(15–31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.Type: GrantFiled: December 30, 1999Date of Patent: June 6, 2006Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Jüppner
-
Patent number: 7022815Abstract: Novel parathyroid hormone(PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.Type: GrantFiled: September 29, 2000Date of Patent: April 4, 2006Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Jüppner
-
Publication number: 20050272660Abstract: Novel parathyroid hormone (PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.Type: ApplicationFiled: July 8, 2005Publication date: December 8, 2005Inventors: Thomas Gardella, Henry Kronenberg, John Potts, Harald Juppner